[go: up one dir, main page]

NI201300124A - Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias. - Google Patents

Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias.

Info

Publication number
NI201300124A
NI201300124A NI201300124A NI201300124A NI201300124A NI 201300124 A NI201300124 A NI 201300124A NI 201300124 A NI201300124 A NI 201300124A NI 201300124 A NI201300124 A NI 201300124A NI 201300124 A NI201300124 A NI 201300124A
Authority
NI
Nicaragua
Prior art keywords
treatment
prevention
compounds
pharmaceutical compositions
adherences
Prior art date
Application number
NI201300124A
Other languages
English (en)
Inventor
Gennadievich Shurygin Mikhail
Aleksandrovna Shurygina Irina
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2011119848/15A external-priority patent/RU2011119848A/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of NI201300124A publication Critical patent/NI201300124A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
    • C08L79/06Polyhydrazides; Polytriazoles; Polyamino-triazoles; Polyoxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere al campo de la farmacia, medicina clinica y experimental y la medicina veterinaria, y en particular, a nuevos compuestos inhibitorios de una p38 MAP quinasa con una estructura del tipo (I) - (VI) que pueden ser utilizados para el tratamiento o profilaxis de adherencia. La invención da a conocer composiciones farmacéuticas que contienen una cantidad eficaz de la sustancia SB203580 o uno de los compuestos del tipo (I) - (VII) o una combinación de los mismos y un vehículo farmacéuticamente aceptable, un diluyente o un excipiente. También se describe el uso de la sustancia SB203580 como un agente que tiene actividad anti-adherencia. También se describe: un método para la profilaxis y/o tratamiento de una enfermedad o una condición en la cual existe la posibilidad de la formación y/o el crecimiento de las adherencias que hace que sea posible prescindir de la administración adicional de una preparación en el post período de la operación.
NI201300124A 2011-05-17 2013-11-15 Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias. NI201300124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (ru) 2011-05-17 2011-05-17 Способ профилактики спайкообразования
RU2011153043 2011-12-26

Publications (1)

Publication Number Publication Date
NI201300124A true NI201300124A (es) 2014-02-25

Family

ID=47176372

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300124A NI201300124A (es) 2011-05-17 2013-11-15 Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias.

Country Status (31)

Country Link
US (2) US10172952B2 (es)
EP (2) EP2716684B1 (es)
JP (2) JP5936683B2 (es)
KR (2) KR20170034950A (es)
CN (1) CN103534293B (es)
AP (1) AP3694A (es)
AU (3) AU2012257347A1 (es)
BR (1) BR112013029616B1 (es)
CA (1) CA2836268C (es)
CL (1) CL2013003305A1 (es)
CO (1) CO6801779A2 (es)
CR (1) CR20130600A (es)
CY (1) CY1122190T1 (es)
DK (1) DK2716684T3 (es)
DO (1) DOP2013000266A (es)
EA (1) EA025493B1 (es)
GE (1) GEP201706614B (es)
IL (1) IL229423B (es)
LT (1) LT2716684T (es)
MA (1) MA35189B1 (es)
MX (2) MX369019B (es)
NI (1) NI201300124A (es)
PE (1) PE20141161A1 (es)
PH (1) PH12013502381B1 (es)
PL (1) PL2716684T3 (es)
RS (1) RS59382B1 (es)
RU (1) RU2582975C2 (es)
SI (1) SI2716684T1 (es)
SV (1) SV2013004582A (es)
WO (1) WO2012156938A1 (es)
ZA (1) ZA201308542B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170034950A (ko) * 2011-05-17 2017-03-29 조인트 스톡 컴퍼니 “파르마신세즈” 부착과정의 예방과 치료를 위한 p38 MAP 키나아제 저해제 조성물
RU2745965C1 (ru) * 2020-11-23 2021-04-05 Галина Анатольевна Пучкина Способ профилактики послеоперационного спаечного процесса органов малого таза
RU2749435C1 (ru) * 2020-11-27 2021-06-10 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Способ лечения энтеральной недостаточности при воспалительных и травматических повреждениях брюшины

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
JPH11510511A (ja) * 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド 2,5−置換アリールピロール、この化合物を含有する組成物及び使用方法
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5894971A (en) 1998-02-02 1999-04-20 Huang; Te Chien Tool holder for attaching tools to user's hand
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
HUP0303763A3 (en) * 2000-08-17 2004-06-28 Pfizer Substituted imidazoles as tafia inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2003249977A1 (en) * 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
PT1928454E (pt) * 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
CA2625426A1 (en) * 2005-09-22 2007-03-29 Hadasit Medical Research Services & Development Limited Dextran and arabinogalactan conjugates of therapeutically active compounds
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
CN101848739A (zh) * 2007-08-28 2010-09-29 T·阿萨纳夏季斯 手术用水凝胶
RU2363476C1 (ru) 2007-12-20 2009-08-10 Марина Сергеевна Гомон Способ профилактики образования послеоперационных спаек
WO2009103821A2 (de) * 2008-02-23 2009-08-27 Virologik Gmbh Mittel zur behandlung von virusinfektionen
US8205286B1 (en) 2008-10-21 2012-06-26 Milagros Diaz Pillow for female breasts
KR20170034950A (ko) * 2011-05-17 2017-03-29 조인트 스톡 컴퍼니 “파르마신세즈” 부착과정의 예방과 치료를 위한 p38 MAP 키나아제 저해제 조성물
CA2846143A1 (en) 2013-03-13 2014-09-13 Evan J. Falck Helmet pillow

Also Published As

Publication number Publication date
DK2716684T3 (da) 2019-09-30
SI2716684T1 (sl) 2019-11-29
CR20130600A (es) 2014-04-29
CA2836268A1 (en) 2012-11-22
NZ618882A (en) 2016-03-31
PE20141161A1 (es) 2014-10-01
CO6801779A2 (es) 2013-11-29
US20190125886A1 (en) 2019-05-02
EP3569636A1 (en) 2019-11-20
US10172952B2 (en) 2019-01-08
AP3694A (en) 2016-04-30
JP2014515057A (ja) 2014-06-26
IL229423A0 (en) 2014-01-30
ZA201308542B (en) 2014-07-30
CL2013003305A1 (es) 2014-07-18
RU2582975C2 (ru) 2016-04-27
BR112013029616A2 (pt) 2020-08-25
AU2012257347A1 (en) 2014-01-09
IL229423B (en) 2018-04-30
PL2716684T3 (pl) 2020-01-31
PH12013502381A1 (en) 2014-02-10
MA35189B1 (fr) 2014-06-02
EP2716684A1 (en) 2014-04-09
RS59382B1 (sr) 2019-11-29
WO2012156938A1 (ru) 2012-11-22
CN103534293A (zh) 2014-01-22
EA025493B1 (ru) 2016-12-30
KR20140074259A (ko) 2014-06-17
SV2013004582A (es) 2018-11-12
CY1122190T1 (el) 2020-11-25
MX382507B (es) 2025-03-13
DOP2013000266A (es) 2014-06-01
JP5936683B2 (ja) 2016-06-22
KR20170034950A (ko) 2017-03-29
RU2013155582A (ru) 2015-06-27
US10493164B2 (en) 2019-12-03
MX2019011386A (es) 2019-10-30
AU2015213303A1 (en) 2015-09-03
US20140079663A1 (en) 2014-03-20
EA201301275A1 (ru) 2014-03-31
AU2017221883B2 (en) 2019-06-20
AP2013007258A0 (en) 2013-11-30
MX369019B (es) 2019-10-24
EP2716684B1 (en) 2019-06-26
CA2836268C (en) 2018-07-03
BR112013029616B1 (pt) 2022-09-20
AU2017221883A1 (en) 2017-09-28
PH12013502381B1 (en) 2021-03-26
EP2716684A4 (en) 2015-07-15
CN103534293B (zh) 2015-10-21
LT2716684T (lt) 2019-09-25
MX2013013409A (es) 2014-07-11
HK1189012A1 (en) 2014-05-23
JP2016175931A (ja) 2016-10-06
GEP201706614B (en) 2017-02-10

Similar Documents

Publication Publication Date Title
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
NI201300124A (es) Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
MX380172B (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
CU20130154A7 (es) Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias
ECSP13012369A (es) Agentes terapéuticos 976
AR120578A1 (es) DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5
FI20106293A0 (fi) Uudet farmaseuttiset koostumukset
AR108792A1 (es) Composiciones que comprenden timolol